Previous 10 | Next 10 |
home / stock / phmmf / phmmf news
Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants - The final results of the APLICOV-PC study (Phase I-II), which were initially released last May ...
The following slide deck was published by Pharma Mar, S.A. in conjunction with this Read more ...
- Lurbinectedin is approved under "Accelerated Approval" based on overall response rate and duration of response demonstrated in an open-label, monotherapy clinical trial. - The anti-tumor compound lurbinectedin will be marketed under the brand name Zepzelca ™ . - Lurbinected...
MADRID , April 28, 2020 /PRNewswire/ -- PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin ® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AE...
Pharma Mar SA (PHMMF) Conference Call to Discuss Jazz Pharmaceuticals License Agreement for Lurbinectedin in the U.S. January 9, 2020 8:00 AM ET Company Participants José Luis Moreno – Director of Investor Relations & Capital Markets Pascal Besman – U.S. Chie...
MADRID , Oct. 19, 2018 /PRNewswire/ -- Sylentis, PharmaMar Group (MCE: PHM), has announced today that it has reached its target of recruiting 300 patients for the Phase III trial "HELIX" [1] for the treatment of the signs and symptoms of dry eye disease. PharmaMar estimate tha...
MADRID , September 24, 2018 /PRNewswire/ -- The results are from Cohort B of the Phase I/II Study in patients with relapsed S mall C ell L ung C ancer (SCLC) . This study preceded the Phase III ATLANTIS s tudy with the same doses and a similar popul...
Akzo Nobel ( OTCQX:AKZOY +2.9% ) has acquired Xylazel, a 100% subsidiary of Pharma Mar ( OTCPK:PHMMF ), strengthening its business and becoming a leader in the decorative paints market in Spain. More news on: Akzo Nobel N.V. ADR, Pharma Mar SA, Akzo Nobel N.V., Merger & acquisition...
MADRID , Sept. 7, 2018 /PRNewswire/ -- Pharma Mar, S.A. (MCE: PHM) ("Pharma Mar" or the "Company") is announcing its intention to conduct a registered public offering of American Depositary Shares representing its shares in the United States. This was previously announced as one of t...
MADRID , September 6, 2018 /PRNewswire/ -- Th e results are from Cohort B of the P hase I /II Study in patients with s mall- c ell l ung c ancer, a study that predated the Phase II I ATLANTIS Study at the same dose level in a s imil...
News, Short Squeeze, Breakout and More Instantly...
Pharma Mar SA Company Name:
PHMMF Stock Symbol:
OTCMKTS Market:
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...